Details for New Drug Application (NDA): 202150
✉ Email this page to a colleague
NDA 202150 describes MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, which is a drug marketed by Chartwell Rx, Glenmark Pharms, Heritage, and Teva, and is included in four NDAs. Additional details are available on the MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE profile page.
The generic ingredient in MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; moexipril hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; moexipril hydrochloride profile page.
The generic ingredient in MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; moexipril hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; moexipril hydrochloride profile page.
Summary for 202150
| Tradename: | MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE |
| Applicant: | Heritage |
| Ingredient: | hydrochlorothiazide; moexipril hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 12.5MG;7.5MG | ||||
| Approval Date: | Mar 7, 2014 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 12.5MG;15MG | ||||
| Approval Date: | Mar 7, 2014 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;15MG | ||||
| Approval Date: | Mar 7, 2014 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
